High Court Rejects Sanofi Inequitable Conduct Appeal

Law360, New York (April 27, 2009, 12:00 AM EDT) -- The U.S. Supreme Court has declined to hear an appeal brought by the subsidiaries of Sanofi-Aventis over lower court findings that patents for Lovenox were invalid because of inequitable conduct, leaving questions surrounding the doctrine murky and paving the way for a generic version of the anti-clotting drug.

The high court on Monday denied the petition for writ of certiorari brought by Aventis Pharma SA and Aventis Pharmaceuticals Inc., keeping intact the U.S. Court of Appeals for the Federal Circuit’s 2-1 opinion in favor of generics...
To view the full article, register now.